Last reviewed · How we verify
NCT06960759
Mechanisms of Change in Behavioral Cough Suppression Therapy for Refractory Chronic Cough
Phase 2 trial testing Behavioral cough suppression therapy combined with inactive inhaled drug (BCS+Sham) in Chronic Cough (CC) in 135 participants. Not yet recruiting.
30 June 2029
Quick facts
| Lead sponsor | University of Montana |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 135 |
| Start date | 15 May 2026 |
| Primary completion | 30 June 2029 |
| Estimated completion | 31 March 2030 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- Behavioral cough suppression therapy combined with inactive inhaled drug (BCS+Sham)
- Behavioral cough suppression therapy combined with capsaicin inhalation (BCS+CAP)
Conditions studied
- Chronic Cough (CC) — all drugs for Chronic Cough (CC) →
- Refractory Chronic Cough — all drugs for Refractory Chronic Cough →
- Unexplained Chronic Cough — all drugs for Unexplained Chronic Cough →
Sponsor
University of Montana
Who can join
Adults 18 to 99, any sex, with Chronic Cough (CC) or Refractory Chronic Cough. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is testing new ways to help people who have chronic cough that has not improved with typical treatments. One approach is called behavioral cough suppression (BCS) therapy, which teaches people techniques to stop themselves from coughing. Another approach uses a natural substance found in chili peppers (capsaicin) to help reduce the body's sensitivity to cough triggers. In this study, we will test two treatments and include one no-treatment control group. The control group will undergo baseline testing, cough monitoring, and an fMRI brain scan and will be offered BCS at end of study participation. The two treatments include: * BCS therapy with capsaicin (BCS+CAP), * BCS therapy with a placebo (BCS+Sham), The investigators will enroll 135 adults with refractory chronic cough (RCC). 100 participants who qualify and are willing and able to complete 14 study visits in the clinic and two online study visits will be randomly assigned to one of the two treatments. The no-treatment control group (n=35) will be recruited from adults with RCC who are willing to complete baseline testing and fMRI but are not able or willing to attend 14 study clinic visits. These participants will not be randomized. The investigators want to find out how these treatments affect: * How sensitive someone is to things that make them cough, * How well they can hold back a cough when they try, * How their brain responds to things that cause an urge-to-cough, * And how much their coughing affects their quality of life. The investigators believe both treatments will reduce sensitivity to cough stimulants, reduce cough severity, and improve quality of life, but BCS+CAP treatment will work better than. BCS+Sham.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06960759
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Cough (CC)
Currently open trials in the same condition.
- NCT07085975 — The Safety, Feasibility, and Repeatability of Inhaled ATP Cough Challenges · Phase 1 · recruiting
- NCT06634823 — Efficacy of Intramuscular Steroid Injection for Chronic Cough. · EARLY_PHASE1 · recruiting
- NCT06600646 — Investigating the Role of ATP Production by Airway Epithelium in Patients With Refractory and Unexplained Chronic Cough · recruiting
Other University of Montana trials
Trials by the same sponsor.
- NCT07254689 — The Food for Health Study · NA · recruiting
- NCT06887647 — Physical Therapy for Montana Children With NMD Using Hippotherapy and the Equine Environment · NA · recruiting
- NCT06788145 — Enhancing Social Connections Among Rural Community Members With Disordered Eating · NA · not yet recruiting
- NCT05763537 — Understanding the Role of Doulas in Supporting People With PMADs · NA · recruiting
- NCT06384625 — Developing and Evaluating an Indoor Air Pollution Intervention Among Cardiovascular Patients: the AIRWISE Study · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06960759 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Montana
- Last refreshed: 6 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06960759.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing